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Available online 8 June 2016Serum lipid management in patients aged ≥75 has not been precisely explored. We, therefore, compared the
serum lipid management between the two age groups with and without coronary heart disease (CHD).
We, therefore, retrospectively reviewedmedical charts of patients who were hospitalized in the departments of
internal medicine during a period of 14 months. Serum lipid goal attainment was explored by applying the lipid
goals for patients aged b75 to those aged ≥75.
In 1988 enrolled patients, 717 subjects (36.1%) were aged ≥75. Among them, 41.3% and 32.4% of the patients had
CHD, 44.2% and 41.0% were primary prevention at high-risk, and 14.5% and 14.6% were primary prevention at
moderate-risk in patients aged ≥75 and aged b75, respectively. Serum LDL-C goal achievement rates in CHD
were 66.9% and 65.0% in patients aged ≥75 and b75, respectively (p = 0.334). In the primary prevention at
high-risk, these rates were 73.5% and 63.3%, in patients aged ≥75 and b75, respectively (p = 0.001). They
were 77.9% and 58.1% in primary prevention at moderate-risk aged ≥75 and b75, respectively (p b 0.001). In
CHD, lipid-lowering medication subscription rates were signiﬁcantly lower in patients aged ≥75 (60.1%) than
those aged b75 (73.8%, p b 0.001).
In conclusion, in CHD, serum lipid goal attainment was comparable between the two age groups although the
lipid-lowering drugs were less frequently prescribed in patients aged ≥75.Without CHD, it was signiﬁcantly bet-
ter in patients aged ≥75 than those aged b75 although the lipid-lowering drug subscription rates were compara-
ble between the two age groups.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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The incidence and prevalence of atherosclerotic cardiovascular
disease (ACVD) increase with age (de Ruijter et al., 2009; Berthold and
Gouni-Berthold, 2011; Phan and Bittner, 2014; McDermott, 2007;
Petersen et al., 2005; Rosamond et al., 2007), and the majority of
ACVD events occur after age 70 years (Stone et al., 2014). In 2009, the
annual mortalities from acute myocardial infarction per 100,000
Japanese population were 12.4 and 18.4 in people aged 50 to 54 years
and 55 to 59 years, respectively. These rates were 127.8 and 215.0 in
the older people aged ≥65 years and ≥75 years, respectively. Thus,ume).
. This is an open access article undermore than 10-fold higher ACVD mortality was observed in the elderly
(≥75) age group when compared to the middle (50 to 59) age group
(Japan Atherosclerosis Society, 2014). Because demographic aging is
proceeding at an unprecedented speed in Japan, the incidence for
ACVD is also predicted to be increasing. Dyslipidemia, especially the
high LDL cholesterol (LDL-C) level, is one of themost important risk fac-
tors for ACVD; therefore, management of LDL-C is extremely important
for preventing ACVD in the older population. However, the importance
of dyslipidemia as an ACVD risk factor in older adults appeared contro-
versial (Ettinger et al., 1992). Several studies have suggested that the as-
sociation between cholesterol levels and ACVD weakens with age and
that there may be little potential beneﬁt from screening and treating
older patients with dyslipidemia (Gordon and Rifkind, 1989; Mariotti
et al., 1986; Garber et al., 1991). Conversely, some investigators havethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ACVD in the elderly (Benfante and Reed, 1990; Barrett-Connor et al.,
1984; Rubin et al., 1990), and lowering serum cholesterol in the elderly
may have a greater impact on ACVD than in the middle age people be-
cause the absolute attributable risk of ACVD from dyslipidemia is great-
er in the older age group than in the middle age group, although the
relative risk of ACVD derived from dyslipidemia is smaller in the older
age group than in the middle age group.
The Japan Atherosclerosis Society guidelines for prevention of ath-
erosclerotic cardiovascular diseases 2012 (JAS2012-GL) suggest the fol-
lowing: Subjects with dyslipidemia whose ages are between 65 and 74
should be treated in the same way as those aged below 65 to achieve
their serum lipid goals. In cases of subjects with dyslipidemia whose
ages are no less than 75 (≥75), patientswithprimary prevention for cor-
onary heart disease (CHD) can be treated individually by the speciﬁc de-
cision of the attending physician, although dyslipidemic patients with
secondary prevention for CHD should be treated equally to those
whose ages are below 65 to achieve their serum lipid goals (Japan
Atherosclerosis Society, 2014). We, therefore, anticipated that the lipid
goal attainment in CHD(secondary prevention)maybe similar between
patients aged ≥75 and b75 and that it may be better in patients aged
b75 than in those aged ≥75whose serum lipid control may not beman-
datory in some cases.
Thus, to examinewhether patients with dyslipidemia aged ≥75 (the
elderly group) are treated differently from those aged b75 (the non-
elderly group), serum lipid goal achievement rates were compared by
applying the lipid goal for the patients aged b75 to those aged ≥75 by
use of the JAS-GL2012. In addition, those rates were further compared
between the two age groups in different risk category subgroups, such
as high-risk and moderate-risk patients with primary prevention for
CHD and those with secondary prevention for CHD. Furthermore, con-
tents of lipid-lowering medication were compared between the elderly
and non-elderly groups.2. Methods
2.1. Study population
Medical charts of all the patients who were hospitalized in the
Departments of Nephrology, Diabetes, Neurology, Respiratory Med-
icine and Cardiology, at Kobe City Medical Center General Hospital,
Kobe, Japan, from April 1st, 2012 to May 31st, 2013 were retro-
spectively reviewed. This hospital has 700 beds, which comprises
approximately 4.6% of the total number of the hospital beds
(15,367) in Kobe City, whose population is 1,535,037. Subjects
who underwent regular dialysis because of chronic renal failure
or without serum lipid data were excluded. Chronic kidney disease
(CKD) at the stage III or higher, according to the guideline from the
Japanese Society of Nephrology, was regarded as a high risk for
ACVD. Diabetes mellitus (DM) was diagnosed according to the
guideline from the Japan Diabetes Society. CHD was deﬁned as
myocardial infarction, angina pectoris, or history of percutaneous
coronary intervention (PCI) or coronary artery bypass graft (CABG) sur-
gery which was described in the medical chart. We have assessed their
medical conditions by reading the medical chart one by one, and con-
ﬁrmed them by, at least, two different investigators. LDL-C levels were
calculated by Friedewald's formula. When serum TG levels were
above 200mg/dL, measured values of LDL-C by a direct LDL-Cmeasure-
ment kit from Sekisui Medical Co. Ltd. were utilized. Direct measure-
ment of LDL-C was performed in the clinical laboratory at the hospital
as a part of clinical practice. When lipid levels were evaluated more
than once, their steady state levels after admission were utilized. In
this study, CKD group (CKD-G) did not include CKD with CHD or DM,
and DM group (DM-G) did not contain DM with CHD, because of the
risk stratiﬁcation under the JAS-GL. This study protocol has beenapproved by the ethical committees in Kobe CityMedical Center Gener-
al Hospital and Kobe Gakuin University.
2.2. Statistical analysis
Continuous variables are presented as mean ± standard error of
mean (SEM), and categorical variables are shown as percentages and
numbers. Continuous variables were compared using the Student's
t-test and Welch's t-test, if the Levene test showed the equal and
unequal variance, respectively. The signiﬁcance in the differences for
categorical variables was determined by the χ2 test. Moreover, supple-
mentary residual analysis was performed for comparisons of more
than two categories. All statistical analyses were carried out using IBM
SPSS Statistics 23 (SPSS Inc.). P values below 0.05 (p b 0.05) were con-
sidered as statistically signiﬁcant.
3. Results
3.1. Patient enrollment
Medical charts of all the 3785 patients whowere hospitalized in the
Departments of Nephrology, Diabetes, Neurology, RespiratoryMedicine
and Cardiology at Kobe CityMedical Center General Hospital, fromApril
1st, 2012 to May, 31st, 2013 were retrospectively reviewed. Sixteen
hundred and sixty (1660) subjects without lipid data, as well as 137
patients who underwent regular dialysis because of chronic renal fail-
ure, were excluded. As a result, a total of 1988 patients were enrolled.
The numbers of patients who were enrolled from Departments of
Nephrology, Diabetes, Neurology, Respiratory Medicine and Cardiology
were 180, 176, 41, 277 and 1314, respectively.
3.2. Patient characteristics
Characteristics of enrolled patients are summarized in Table 1. There
was a signiﬁcant difference in the proportion of patients aged ≥75
(overall: p b 0.001), due to the higher prevalence of patients aged ≥75
in Department of Respiratory Medicine (p b 0.01) and the lower preva-
lence of those in Departments of Nephrology (p b 0.05) and Diabetes
(p b 0.01). BMI (p b 0.001), all lipid levels (p b 0.001) and eGFR
(p b 0.001) were signiﬁcantly lower in patients aged ≥75 than those
aged b75. In addition, the prevalence of female (p b 0.001), HT (p =
0.001), CKD (p b 0.001) and CHD (p b 0.001) was signiﬁcantly higher
in patients aged ≥75 than those aged b75.
3.3. Comparison of LDL-C and non-HDL-C levels and their target level
achievement rates between male and female
To explore whether the gender imbalance between patients aged
≥75 and b75 can be the cause for the differences in lipid levels between
the two age groups, lipid proﬁles were compared betweenmale and fe-
male. As shown in Table 2, LDL-C (p b 0.001), HDL-C (p b 0.001) non-
HDL-C (p b 0.001) levels were signiﬁcantly higher in female than in
male. However, TG (p b 0.001) level was signiﬁcantly lower in female
than in male. LDL-C target level achievement rates were 68.4% and
66.8%, in male and in female, respectively (p= 0.255). These rates for
non-HDL-C were 70.8% and 70.3%, respectively (p = 0.427). Thus,
lipid target level achievement rates were comparable between male
and female, although there were signiﬁcant differences in lipid levels.
3.4. Comparison of risk stratiﬁcation proﬁles between the elderly and the
non-elderly age groups
Prevalence of CHD was 41.3% and 32.4% in patients aged ≥75 and
b75, respectively, (Fig. 1). In addition, none of the patients in patients
aged ≥75 was stratiﬁed into low-risk, even though 12.0% of the patients
were stratiﬁed into low-risk in patients aged b75 (Fig. 1). Prevalence of
Table 1
Characteristics of enrolled patients.
Enrolled patients Aged ≥75 years Aged b75 years p
Department b0.001
Nephrology 100 (180) 27.8 (50) 72.2 (130) b0.05
Diabetes 100 (176) 21.0 (37) 79.0 (139) b0.01
Neurology 100 (41) 39.0 (16) 61.0 (25)
Respiratory Medicine 100 (277) 44.8 (124) 55.2 (153) b0.01
Cardiology 100 (1314) 37.3 (490) 62.7 (824)
Total 100 (1988) 36.1 (717) 63.9 (1271)
Age, y 67.7 ± 0.3 (1988) 81.2 ± 0.2 (717) 60.0 ± 0.4 (1271)
Mean body mass index (kg/m)2 23.1 ± 0.1 (1939/1988) 22.1 ± 0.1 (695/717) 23.7 ± 0.2 (1244/1271) b0.001
Gender b0.001
Male 64.4 (1280) 58.6 (420) 67.7 (860)
Female 35.6 (708) 41.4 (297) 32.3 (411)
Risk factors
HT 57.8 (1150) 62.6 (449) 55.2 (701) 0.001
CKD 40.4 (804) 52.7 (378) 33.5(426) b0.001
DM 36.1 (718) 34.3 (246) 37.1 (472) 0.113
CHD 35.6 (708) 41.3 (296) 32.4 (412) b0.001
Lipid proﬁles
LDL-C (mg/dL) 100.3 ± 0.7 (1981/1988) 94.3 ± 1.1 (715/717) 103.7 ± 0.9 (1266/1271) b0.001
TG (mg/dL) 132.7 ± 1.8 (1986/1988) 118.4 ± 2.5 (716/717) 140.7 ± 2.5 (1270/1271) b0.001
HDL-C (mg/dL) 51.3 ± 0.4 (1988) 49.6 ± 0.6 (717) 52.3 ± 0.5 (1271) b0.001
non-HDL-C (mg/dL) 124.9 ± 0.9 (1831/1988) 116.8 ± 1.3 (679/717) 129.7 ± 1.1 (1152/1271) b0.001
eGFR (mL/min/1.73 m2 ) 64.9 ± 1.0 (1974/1988) 55.4 ± 0.9 (715/717) 70.3 ± 1.4 (1259/1271) b0.001
Values are expressed as percent (n) ormean± SEM (n). HT, hypertension; CKD, chronic kidney disease, DM, diabetes mellitus; LDL-C, LDL cholesterol; TG, triglycerides; HDL-C, HDL cho-
lesterol; non-HDL-C, non-HDL cholesterol; eGFR, estimated glomerular ﬁltration rate.
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tients aged ≥75 and b75, respectively, (Fig. 1).
3.5. Comparison of LDL-C and non-HDL-C target level achieving rates
between the elderly and the non-elderly age groups
LDL-C and non-HDL-C target level achievement rates were 71.4%
and 75.6% in patients aged ≥75, and these rates were 65.8% and 67.7%,
respectively, in patients aged b75. Thus, to our surprise, LDL-C and
non-HDL-C target level achievement rates were signiﬁcantly higher in
patients aged ≥75 than those aged b75 (p = 0.006 and p b 0.001,
respectively).
Lipid target level attainment was further evaluated in the different
risk category subgroups. In CHD, LDL-C and non-HDL-C target level
achievement rates were 66.9% and 74.7%, respectively, in patients
aged ≥75, and they were 65.0% and 69.8%, respectively, in patients
aged b75. Thus, in CHD, LDL-C and non-HDL-C goal attainment was
comparable between patients aged ≥75 and those aged b75 (p =
0.334 and p=0.092, respectively, Fig. 2A andB). In the primary preven-
tion at high-risk subgroup, however, LDL-C and non-HDL-C goal attain-
ment rates were higher in patients aged ≥75 (73.5% and 75.1%,
respectively) than those aged b75 (63.3% and 64.3%, respectively).
These differences were statistically signiﬁcant (p = 0.001 and p =
0.001, respectively, Fig. 2C and D). In the primary prevention at
moderate-risk subgroup, LDL-C and non-HDL-C goal attainment also
was better in patients aged ≥75 (77.9% and 79.8%, respectively) than
those aged b75 (58.1% and 59.1%, respectively). These differences also
were statistically signiﬁcant (p b 0.001, Fig. 2E and F). In CKD-G, LDL-C
and non-HDL-C goal attainment rates were higher in patients agedTable 2
Comparison of lipid proﬁles between male and female.
Male Female P
LDL-C (mg/dL) 97.2 ± 0.9 (1273/1280) 106.0 ± 1.3 (708) b0.001
TG (mg/dL) 137.8 ± 2.4 (1279/1280) 123.4 ± 2.6 (707/708) b0.001
HDL-C (mg/dL) 48.7 ± 0.4 (1280) 56.2 ± 0.6 (708) b0.001
non-HDL-C (mg/dL) 122.0 ± 1.0 (1165/1280) 130.1 ± 1.6 (666/708) b0.001
Values are expressed as mean ± SEM (n).≥75 (70.2% and 69.5%, respectively) than those aged b75 (58.1% and
59.1%, respectively), which were statistically signiﬁcant differences
(p = 0.018 and p = 0.036, respectively). In DM-G, in addition, they
were 78.0% and 80.5%, respectively, in patients aged ≥75, and 69.3%
and 71.5%, respectively, in those aged b75, whichwere also signiﬁcantly
higher in patients aged ≥75 than those aged b75 (p = 0.044 and p =
0.036 for LDL-C and non-HDL-C, respectively).
3.6. Comparison of lipid-lowering medication prescription rates between
the elderly and the non-elderly age groups
The prescription rates of lipid-lowering drugs were compared be-
tween patients aged ≥75 and those aged b75. Lipid-lowering medica-
tion prescription rates were 41.6% and 39.9% in patients aged ≥75 and
b75, respectively. Thus, lipid-lowering medication prescription rates
appeared to be comparable (p= 0.248) between the two age groups.
Lipid-lowering medication prescription rates were further com-
pared between these two age groups in the different risk category sub-
groups. In CHD, lipid-lowering medication subscription rates were
signiﬁcantly lower in patients aged ≥75 (60.1%) than in those aged
b75 (73.8%, p b 0.001, Fig. 3A). In the primary prevention at high-risk
subgroup, these rates were comparable between the two age groups.
(31.2% and 30.7%, respectively, p= 0.467, Fig. 3B). In the primary pre-
vention at moderate-risk subgroup, lipid-lowering medicationFig. 1. Comparison of risk stratiﬁcation in patients between patients aged ≥75 (panel
A) and b75 (panel B).
Fig. 2. Comparison of LDL-C andnon-HDL-C target level attainment betweenpatients aged ≥75 and b75 in various risk category subgroups. LDL-C (panels A, C, E) andnon-HDL-C (panels B,
D, F) target level achievement rates were compared between patients aged ≥75 and b75 in various risk category subgroups, such as CHD (panels A, B), primary prevention at high-risk
(panels C, D) and moderate-risk (panels E, F) subgroups. Values are expressed as percent. The p values were derived from χ2 statistics.
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(20.2% and 14.0% for patients aged ≥75 and b75, respectively, p =
0.114, Fig. 3C). In CKD-G, they were 31.9% and 26.2% in patients aged
≥75 and b75, respectively (p=0.160). In DM-G, they were comparable
between the two age groups (35.8% and 36.7%, respectively, p=0.471).
Thus, lipid-lowering medication was less frequently prescribed in pa-
tients aged ≥75 than those aged b75 in the secondary prevention for
CHD, and was almost equally prescribed in patients aged ≥75 and b75
in the primary prevention at high-risk andmoderate-risk subgroups, in-
cluding CKD-G and DM-G. These results were quite different fromwhat
we had anticipated before this study.
In addition, contents of the lipid-lowering medication were com-
pared between patients aged ≥75 and b75. Prescription rates for drug
combinations and monotherapies of lipid-lowering drugs werecompared between two age groups in the total enrolled patients
(Table 3) and in the patients with CHD (Table 4). The combination of
statin plus EPA was more frequently prescribed in patients aged b75
than in those aged ≥75, in the total enrolled patients (Table 3) as well
as in those with CHD (Table 4). These differences were statistically sig-
niﬁcant (p= 0.002 and p= 0.001, respectively). In CHD, furthermore,
statin monotherapy was also signiﬁcantly more prevalent in patients
aged b75 than those aged ≥75 (p= 0.016, Table 4).
4. Discussion
Atherosclerosis is a continuous degenerative process, and its burden
increases progressively with aging (Ulucam, 2012). Dyslipidemia is one
of the most important risk factors in the development of atherosclerosis.
Fig. 3. Comparison of lipid-lowering medication prescription rates between patients aged ≥ 75 and b 75 in various risk category subgroups Lipid-lowering medication prescription rates
were compared between patients aged ≥75 and b75 in various risk category subgroups, such as CHD (panel A), primary prevention at high-risk (panel B) and moderate-risk (panel
C) subgroups. Values are expressed as percent. The p values were derived from χ2 statistics.
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primary prevention for CHD should be individually treated ﬂexibly by
the decisions of their attending physicians based upon the condition of
each patient, such as accompanying other chronic diseases, frailty, drug
tolerability, and social activities. On the other hand, patients aged 65–74
with dyslipidemia should be treated in the same way as those aged b65
to achieve their serum lipid goals (Japan Atherosclerosis Society, 2014).
The PROSPER trial showed that three-year statin treatment in pa-
tients aged 70 to 82 years, including secondary prevention patients, de-
creased the risk of death from CHD plus nonfatal myocardial infarction
by 19%, clearly demonstrating that intervention with statins may be in-
dicated for the elderly. A decreased incidence of CHD was more clearly
observed in men than in women, and in secondary prevention patients
compare d to primary prevention patients; however, these differences
were statistically insigniﬁcant (Shepherd et al., 2002). In addition,
meta-analyses of the Cholesterol Treatment Trialists' (CTT) collabora-
tion revealed that patients aged ≥75 tended to be less effective in the
CHD risk reductions by statins than those aged b75; however, they
were not statistically signiﬁcant differences (Baigent et al., 2010).
In the present study, the status of the serum lipid management in
real-world clinical practice has been explored comparing the patientsaged ≥75 to those aged b75. To the best of our knowledge, this is the
ﬁrst report thatwas directed to the elderly patients (aged ≥75) compar-
ing their serum lipid goal attainment rates to those in the non-elderly
(aged b75) patients. In fact, we had supposed that the LDL-C and non-
HDL-C target level achievement rates in patients aged ≥75 may be
lower than those aged b75 in the primary prevention, and that they
may be comparable in the secondary prevention patients, according to
the guideline. Contrary to our expectation, the LDL-C and non-HDL-C
target level achievement rates tended to be higher in the elderly (aged
≥75) patients than those aged b75 in the primary prevention, although
they are comparable between patients aged ≥75 and those aged b75 in
the secondary prevention. In patients aged ≥75 with CHD, lipid-
lowering medication subscription rate was 60.1%, which was lower
than that (73.8%) in patients aged b75. They may result from the fact
that lipid levels in patients aged ≥75 were lower than those in patients
aged b75which appeared to be supported by previous studies (Ettinger
et al., 1992; Schupf et al., 2005).
In the elderly, they more often have advanced presymptomatic
atherosclerotic vascular lesions, which impose CHD events, than in the
non-elderly subjects (Kannel, 2002). Elevated serum cholesterol is asso-
ciated with greater number of CHD events (higher absolute risks) in the
Table 3
Prescription rates for drug combinations and monotherapies of lipid-lowering medica-
tions in total enrolled patients.
Aged ≥75
years
Aged b75
years
p
Quadruple
therapy
Statin, ﬁbrate, ezetimibe,
EPA
0.1 (1) 0.0 (0) 0.361
Triple therapy Statin, ezetimibe, resin 0.0 (0) 0.1 (1) 0.639
Statin, ezetimibe, EPA 0.3 (2) 0.4 () 0.508
Statin, ezetimibe, nicotinic
acid
0.3 (2) 0.0 (0) 0.130
Dual therapy Statin, ﬁbrate 0.1 (1) 0.2 (2) 0.704
Statin, ezetimibe 1.3 (9) 1.2 (15) 0.519
Statin, EPA 0.7 (5) 2.5 (32) 0.002
Statin, nicotinic acid 0.6 (4) 0.7 (9) 0.468
Fibrate, ezetimibe 0.0 (0) 0.1 (1) 0.639
Ezetimibe, EPA 0.1 (1) 0.1 (1) 0.591
Monotherapy Statin 36.3 (260) 33.3 (423) 0.098
Fibrate 0.3 (2) 0.6 (7) 0.312
Ezetimibe 0.3 (2) 0.2 (3) 0.592
EPA 1.0 (7) 0.3 (4) 0.058
Nicotinic acid 0.3 (2) 0.3 (4) 0.626
Without
medication
58.4 (419) 60.1 (764) 0.248
Values are expressed as percent (n).
197R. Shimizu et al. / Preventive Medicine Reports 4 (2016) 192–198elderly than in the middle-aged or younger people. Consequently, re-
ducing cholesterol concentration from high to low may well result in a
greater overall reduction in new CHD events in the elderly population
than in the middle-aged people, who generally have lower absolute
risks (Gobal and Mehta, 2010). Therefore, although the relative risk re-
duction by lipid lowering may be smaller in the elderly than in the
middle-aged subjects, the absolute risk reduction is greater in the elder-
ly (Miettinen et al., 1997; Lewis et al., 1998; Heart Protection Study
Collaborative Group, 2002) because of the higher baseline event rates
(Berthold andGouni-Berthold, 2011). At least, the JAS guideline does in-
dicate that patients, who have already been taking and tolerating
statins, should continue to take these drugs beyond 75 years of age
(Japan Atherosclerosis Society, 2014).
In National Clinical Guideline in the UK, the Guideline Development
Group members were aware that people aged 85 years or older have
greater absolute risks of ACVD events, when compared with people
aged below 85, and that they thus might have a greater likelihood
of clinical beneﬁts with statins (National Clinical Guideline Centre,
2014). Elderly people, in general, are more likely to have otherTable 4
Prescription rates for drug combinations and monotherapies of lipid-lowering medica-
tions in CHD.
Aged ≥75
years
Aged b75
years
p
Quadruple
therapy
Statin, ﬁbrate, ezetimibe, EPA 0.3 (1) 0.0 (0) 0.418
Triple therapy Statin, ezetimibe, resin 0.0 (0) 0.0 (0)
Statin, ezetimibe, EPA 0.7 (2) 1.2 (5) 0.380
Statin, ezetimibe, nicotinic acid 0.3 (1) 0.0 (0) 0.418
Dual therapy Statin, ﬁbrate 0.3 (1) 0.0 (0) 0.418
Statin, ezetimibe 2.4 (7) 2.9 (12) 0.422
Statin, EPA 1.7 (5) 6.6 (27) 0.001
Statin, nicotinic acid 0.3 (1) 1.2 (5) 0.205
Fibrate, ezetimibe 0.0 (0) 0.0 (0)
Ezetimibe, EPA 0.0 (0) 0.0 (0)
Monotherapy Statin 52.0 (154) 60.4 (249) 0.016
Fibrate 0.3 (1) 1.2 (5) 0.205
Ezetimibe 0.3 (1) 0.0 (0) 0.418
EPA 1.0 (3) 0.2 (1) 0.200
Nicotinic acid 0.3 (1) 0.0 (0) 0.418
Without
medication
39.9 (118) 26.2 (108) b0.001
Values are expressed as percent (n).comorbidities, poorer renal function, shorter life expectancy and other
medication. Therefore, it would be recommended that statins should
be prescribed with lower starting doses in the elderly (Stone et al.,
2014; Reiner et al., 2011). There are very few data on cardiovascular
outcomes in patients aged ≥75with primary prevention for CHD. There-
fore, Ezetimibe Lipid Lowering Trial on Prevention of Atherosclerosis in
75 or Older (EWTOPIA75 trial), using ezetimibe and powered for cere-
brovascular and cardiovascular event endpoints, is currently ongoing
in the primary prevention patients aged ≥75 with high LDL-C levels in
Japan since 2009 (The Japan Geriatrics Society, n.d.).
Limitations of the present study may include the fact that this is a
single-center retrospective cross-sectional study in patients who had
been hospitalized in the Departments of Nephrology, Diabetes, Neurol-
ogy, Respiratory Medicine and Cardiology and, therefore, results may
not be generalizable to a broader spectrum of patients aged ≥75. In
the primary prevention, serum lipid levels may be worse managed in
subjects aged ≥75, if whole the outpatients, who had not been hospital-
ized, are included in this study. Especially, elderly subjects with
sarcopenia or frailty would be much less frequently treated with lipid-
lowering medication. Hence, future studies, including community-
based residents with larger sample sizes may be needed to conﬁrm
the ﬁndings of the present study.
In conclusion, serum lipid goal attainmentwas comparable between
the elderly and non-elderly patients with CHD, although the lipid-
lowering drugs were less frequently prescribed in the elderly. Without
CHD, it was signiﬁcantly better in the elderly patients than the non-
elderly subjects, although the lipid-lowering drug subscription rates
were comparable between the elderly and non-elderly. Thus, baseline
LDL-C and non-HDL-C levels before treatment with lipid-lowering
drugs might have appeared higher in the non-elderly patients
with andwithout CHD; therefore, their serum lipidmanagement should
be improved by more aggressive medical treatment according to the
JAS-GL 2012.
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